Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) dropped 0% during trading on Thursday . The stock traded as low as $18.24 and last traded at $18.64. Approximately 48,777,184 shares were traded during trading, an increase of 140% from the average daily volume of 20,284,979 shares. The stock had previously closed at $18.64.

TEVA has been the topic of several analyst reports. BidaskClub lowered shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research report on Friday, October 13th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, October 19th. Barclays set a $19.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, October 20th. Royal Bank of Canada set a $15.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Friday, October 20th. Finally, Evercore ISI set a $38.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, October 25th. Ten investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $21.15.

The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The company has a market cap of $19,300.00, a price-to-earnings ratio of -1.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The firm had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the firm earned $1.38 EPS. The firm’s revenue for the quarter was down 15.9% on a year-over-year basis. analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.75 earnings per share for the current year.

Several large investors have recently bought and sold shares of the business. Financial Sense Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth $775,000. Synovus Financial Corp grew its stake in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Synovus Financial Corp now owns 27,817 shares of the company’s stock worth $530,000 after acquiring an additional 6,029 shares in the last quarter. American International Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 9.3% in the fourth quarter. American International Group Inc. now owns 112,490 shares of the company’s stock worth $2,132,000 after acquiring an additional 9,601 shares in the last quarter. Employees Retirement System of Texas grew its stake in shares of Teva Pharmaceutical Industries by 4.2% in the fourth quarter. Employees Retirement System of Texas now owns 441,359 shares of the company’s stock worth $8,364,000 after acquiring an additional 17,823 shares in the last quarter. Finally, Wetherby Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth $197,000. Institutional investors and hedge funds own 51.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/02/10/teva-pharmaceutical-industries-teva-trading-down-0.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.